METHOD OF SURGICAL TREATMENT USING AUTOLOGOUS CONDITIONED PLASMA

• US 20080166421A1
• Filed: 12/21/2007
• Published: 07/10/2008
• Est. Priority Date: 12/28/2006
• Status: Active Grant

• Current Assignee: Arthrex Incorporated
• Original Assignee: Arthrex Incorporated
• Inventors: Siekmann, Werner, Buhr, Michael, Naudin, Stephane
• Granted Patent: US 8,052,969 B2
• Time in Patent Office: Days
• US Class Current: 424/530
• CPC Class Codes: A61K 35/18 Erythrocytes haemoglobin A61K38/42
• CPC Class Codes: A61M 1/0281 Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
• CPC Class Codes: A61M 1/029 Separating blood components present in distinct layers in a container, not otherwise provided for containers for storing blood or blood components A61J1/05; sampling or analysing blood by separating blood components G01N33/491
• CPC Class Codes: A61M 2202/0415 Plasma

Abstract

A method of providing autologous conditioned plasma (ACP) for treatment of connective tissue injuries. The method comprises the steps of: (i) providing an apparatus comprising a centrifuge and a double syringe, the double syringe including an inner syringe body and an outer syringe body; (ii) drawing autologous blood into the outer syringe body; (iii) subjecting the autologous blood to at least one centrifugation step to obtain an autologous conditioned plasma (ACP); (iv) removing, with the inner syringe body, at least a portion of autologous conditioned plasma (ACP) from the outer syringe body; and (v) inject ACP for treatment of various cartilage or tendon damage or diseases.

Claims

1. A method of surgical treatment using autologous conditioned plasma, comprising:

providing a syringe assembly comprising a first syringe having a first body with a first diameter; and

a second syringe having a second body with a second diameter smaller than the first diameter, the first syringe being in direct fluid communication with the second syringe;

withdrawing blood with the first syringe;

subjecting the syringe assembly to at least one rotational step to obtain an autologous conditioned plasma; and

transferring at least a portion of the autologous conditioned plasma from the first syringe to the second syringe.

2. The method of claim 1, wherein the blood contains a first amount of platelets/microliter and wherein the autologous conditioned plasma contains a second amount of platelets/microliter, wherein the second amount is about twice the first amount.

3. The method of claim 1, wherein the blood contains about 200,000 platelets/microliter and wherein the autologous conditioned plasma contains about 400,000-470,000 platelets/microliter.

4. The method of claim 1, further comprising treating at least a portion of a damaged tissue with the autologous conditioned plasma to facilitate healing of the tissue.

5. The method of claim 4, wherein the treating of the damaged tissue further comprises removing the second syringe from the syringe assembly and injecting, with the second syringe, the autologous conditioned plasma into the damaged tissue.

6. The method of claim 4, wherein the damaged tissue is a joint.

7. The method of claim 4, wherein the damaged tissue is a nerve root or a vertebral joint.

8. The method of claim 4, wherein the damaged tissue is a damaged tendon.

9. A method of treating tissue in a mammal, comprising:

drawing autologous blood from the mammal;

subjecting the autologous blood to a centrifugation process to obtain an autologous conditioned plasma and a residual blood component;

separating the autologous conditioned plasma from the residual blood component; and

injecting the autologous conditioned plasma into the tissue to promote tissue growth.

10. The method of claim 9, wherein the autologous conditioned plasma is injected once a week, for about six weeks.

11. The method of claim 9, further comprising the step of adding an activator to the autologous conditioned plasma after the step of separating the autologous conditioned plasma from the residual blood component, and before the step of injecting the autologous conditioned plasma.

12. The method of claim 9, wherein the steps of subjecting the autologous blood to a centrifugation process, separating the autologous conditioned plasma, and injecting the autologous conditioned plasma are all conducted in a doctor'"'"'s office or in the operating room.

13. The method of claim 9, wherein the step of drawing autologous blood from the mammal is conducted by employing a double-chamber linear syringe.

14. A method of surgical treatment of connective tissue injury, comprising:

providing a double-chamber syringe comprising a first chamber having a first body with a first diameter; and

a second chamber connected to the first chamber and in fluid communication with the first chamber, the second chamber having a second body with a second diameter smaller than the first diameter, the second chamber being located at least partially within the first chamber;

withdrawing autologous blood with the double-chamber syringe so that the autologous blood is temporarily stored within the first chamber;

introducing the double-chamber syringe into a centrifuge and centrifuging the double-chamber syringe to obtain an autologous conditioned plasma in the first chamber;

transferring at least a portion of the autologous conditioned plasma from the first chamber to the second chamber;

disconnecting the second chamber with the autologous conditioned plasma from the first chamber; and

delivering the autologous conditioned plasma to the connective tissue.

15. The method of claim 14, wherein the autologous blood contains a first amount of platelets/microliter and wherein the autologous conditioned plasma contains a second amount of platelets/microliter, the second amount being about twice the first amount.

16. The method of claim 14, wherein the autologous blood contains about 200,000 platelets/microliter and wherein the autologous conditioned plasma contains about 400,000-470,000 platelets/microliter.

17. The method of claim 14, wherein the connective tissue is selected from the group consisting of nerve root, vertebral joint, cartilage and tendon.

18. The method of claim 14, wherein the autologous conditioned plasma is employed for treating chondromalacia I^o-III^o, cartilage damage, cartilage transplantation, tendonesis, ligamentosis, radiculitis, radiculopathy of the cervical or lumbar spine, syndrom of the vertebral column facets, degeneration of spinal disk, or erosive osteochondrosis.